Literature DB >> 14508320

The neuroprotective effect of xenon administration during transient middle cerebral artery occlusion in mice.

H Mayumi Homi1, Noriko Yokoo, Daqing Ma, David S Warner, Nicholas P Franks, Mervyn Maze, Hilary P Grocott.   

Abstract

BACKGROUND: Xenon has been shown to be neuroprotective in several models of in vitro and in vivo neuronal injury. However, its putative neuroprotective properties have not been evaluated in focal cerebral ischemia. The purpose of this study was to determine if xenon offers neuroprotection in a mouse model of middle cerebral artery occlusion.
METHODS: C57BL/6 mice underwent 60 min of middle cerebral artery occlusion. The animals (n = 21 per group) were randomized to receive either 70% xenon + 30% O2, 70% N2O + 30% O2, or 35% xenon + 35% N2O + 30% O2. After 24 h, functional neurologic outcome (on three independent scales: four-point, general, and focal deficit scales) and cerebral infarct size were evaluated.
RESULTS: The 70% xenon + 30% O2 group showed improved functional outcome (median [interquartile range], four-point scale: 2 [2], 70% xenon + 30% O2 versus 3 [2], 70% N2O + 30% O2, P = 0.0061; general deficit scale: 9 [6], 70% xenon + 30% O2 versus 10 [4], 70% N2O + 30% O2, P = 0.0346). Total cerebral infarct volumes were reduced in the 70% xenon + 30% O2 group compared with the 70% N2O + 30% O2 group (45 +/- 17 mm3 versus 59 +/- 11 mm3, respectively; P = 0.0009).
CONCLUSIONS: In this model of transient focal cerebral ischemia, xenon administration improved both functional and histologic outcome.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14508320     DOI: 10.1097/00000542-200310000-00020

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  39 in total

Review 1.  [Current developments in xenon research. Importance for anesthesia and intensive care medicine].

Authors:  A Brücken; M Coburn; S Rex; R Rossaint; M Fries
Journal:  Anaesthesist       Date:  2010-10       Impact factor: 1.041

Review 2.  Inhalational anesthetics as neuroprotectants or chemical preconditioning agents in ischemic brain.

Authors:  Hideto Kitano; Jeffrey R Kirsch; Patricia D Hurn; Stephanie J Murphy
Journal:  J Cereb Blood Flow Metab       Date:  2006-10-18       Impact factor: 6.200

Review 3.  Pharmacologic neuroprotection: the search continues.

Authors:  Hilary P Grocott
Journal:  J Extra Corpor Technol       Date:  2007-12

Review 4.  Intraoperative care for aortic surgery using circulatory arrest.

Authors:  Félix Ezequiel Fernández Suárez; David Fernández Del Valle; Adrián González Alvarez; Blanca Pérez-Lozano
Journal:  J Thorac Dis       Date:  2017-05       Impact factor: 2.895

5.  Modulation by the noble gas argon of the catalytic and thrombolytic efficiency of tissue plasminogen activator.

Authors:  Hélène N David; Benoît Haelewyn; Jean-Jacques Risso; Jacques H Abraini
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-11-11       Impact factor: 3.000

6.  Human recombinant tissue-plasminogen activator (alteplase): why not use the 'human' dose for stroke studies in rats?

Authors:  Benoît Haelewyn; Jean-Jacques Risso; Jacques H Abraini
Journal:  J Cereb Blood Flow Metab       Date:  2010-03-10       Impact factor: 6.200

Review 7.  Considerations for the use of anesthetics in neurotoxicity studies.

Authors:  Sumedha W Karmarkar; Kathleen M Bottum; Shelley A Tischkau
Journal:  Comp Med       Date:  2010-08       Impact factor: 0.982

Review 8.  Anaesthetic-related neuroprotection: intravenous or inhalational agents?

Authors:  Daniela Schifilliti; Giovanni Grasso; Alfredo Conti; Vincenzo Fodale
Journal:  CNS Drugs       Date:  2010-11       Impact factor: 5.749

9.  Xenon is an inhibitor of tissue-plasminogen activator: adverse and beneficial effects in a rat model of thromboembolic stroke.

Authors:  Hélène N David; Benoît Haelewyn; Jean-Jacques Risso; Nathalie Colloc'h; Jacques H Abraini
Journal:  J Cereb Blood Flow Metab       Date:  2010-01-20       Impact factor: 6.200

Review 10.  Bench-to-bedside review: Molecular pharmacology and clinical use of inert gases in anesthesia and neuroprotection.

Authors:  Robert Dickinson; Nicholas P Franks
Journal:  Crit Care       Date:  2010-08-12       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.